Welcome to the Horizon 2020 atherosclerosis research program website
The RadboudUMC group led by Prof. Niels Riksen and Prof. Mihai Netea very recently published cutting edge results in Cell press about influencing our immune system by utilizing the “Trained Immunity” concept, key to the REPROGRAM project. Metabolic induction or trained immunity involves mevalonate pathway, Siroon Bekkering et al., Cell, January 11, 2018 Cholesterol inhibitor
In the high impact European Heart Journal, the REPROGRAM consortium published an invited review of the REPROGRAM concepts and approaches. This open-access article can be found here (doi:10.1093/eurheartj/ehx581) Main message: Chronic inflammatory diseases are the most common diseases of ageing and represent one of our major health threats. These include. most forms of cardiovascular diseases,
Agnieszka Pajak, a REPROGRAM-dedicated PhD-student working at the University Hospital Zurich (Switzerland) on Trained Immunity in rheumatoid arthritis was invited to give a talk at the Annual European Congress of Rheumatology (European League Against Rheumatism, EULAR). The following EULAR congress is planned in Amsterdam (the Netherlands) from 13 till 16 June 2018.
Renewed interest in immune cell metabolism has led to the emergence of a research field aimed at studying the importance of metabolic processes for an effective immune response. In addition to the adaptive immune system, cells of the myeloid lineage have been shown to undergo robust metabolic changes upon activation. In the Cell Metabolism paper, published by
Bonn University (Prof. Eike Latz) and Radboud University Medical Center Nijmegen (Prof. Niels Riksen and Dr. Siroon Bekkering) published a review in the journal Seminars on Immunology in which they discuss the concept of trained innate immunity in the context of a hyperlipidemic environment and atherosclerosis. According to this idea the epigenome of myeloid (progenitor) cells is presumably modified
Jan Schnitzler, poster presentation Renate Hoogeveen, scientific talk Simone Verweij, poster presentation Simone Verweij, electronic poster presentation
In line with the ground-breaking concept of REPROGRAM not only the cholesterol lowering PCSK9 inhibitors seem to be effective. But now, a purely anti-inflammatory cardiovascular trial with the IL-1ß blocker was positive. Thus, both hypotheses seem to be correct, the cholesterol and the inflammation hypotheses of treating cardiovascular disease. The global Phase III CANTOS
Sophie J. Bernelot Moens, junior researcher in the group of Prof. Erik Stroes and Prof. Menno de Winther (Academic Medical Center) recently published her results in European Heart Journal on how PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia. Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies increase hepatic low-density lipoprotein receptor expression and show potent low-density lipoprotein
The group of Prof. Catapano at University of Milano, Italy (IRCCS MultiMedica-MultiMedica SpA, Cardiovascular Department, Atherosclerosis Center) published an highly interesting review on the biological processes of Proprotein Convertase Subtilisin Kexin 9 (PCSK9). PCK9 is a key regulator of low-density lipoprotein receptor levels and LDL-cholesterol levels. The PCSK9 gene is associated with hypocholesterolaemia and protection against cardiovascular disease, setting the stage for
The first informal young REPROGRAM researcher meeting was held at the European Atherosclerosis Society in Prague. REPROGRAM provides an excellent environment for early stage researchers as it brings together senior researchers from different fields of expertise such as cardiovascular diseases, immunology and rheumatology, covering the spectrum of fundamental and clinical studies. Furthermore, life sciences companies are
This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N°667837.